This is

Bayer in Canada

Bayer in Canada

In this age of rapid change, we strive to deliver the world’s best solutions to global challenges in the fields of health and nutrition.

With life expectancy continuing to rise, we improve quality of life for a growing population by focusing our research and development activities on preventing, alleviating and treating diseases. We are also making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials.

In Canada, we have over 1,400 passionate and innovative employees. As a Life Science company we have three divisions – Pharmaceuticals, Consumer Health and Crop Science – and the Radiology business unit.  We are committed to operating sustainably and addressing our social and ethical responsibilities. As we continue to shape our industry, our efforts are catalyzed by focusing on our customers. All of this makes up our corporate purpose: Science for a better life.

News

August 04, 2020

Bayer’s finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetes

• Finerenone significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care • Finerenone significantly reduced the combined key secondary endpoint of cardiovascular death or non-fatal cardiovascular events • Chronic kidney disease impacts 4 in 10 patients with type 2 diabetes and is a deadly condition that is underrecognized • Finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor antagonist to demonstrate renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes Read more
July 23, 2020

Bayer Inc. launches FastTRK, a complimentary clinical testing program for the diagnosis of NTRK gene fusions in TRK fusion cancer patients in Canada

Read more
Bayer News Overview